Payment overview · 2025
General Payments
$129.55
7 reported records · 3 companies
Healthcare provider profile · identity verified
John Jacob, MD
Allopathic & Osteopathic Physicians|Family Medicine · SARASOTA, FL · NPI 1396009122
Verified facts
What the public records show
CMS Open Payments records show John Jacob, MD received $129.55 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 49.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.65 | 49.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.06 | 28.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.84 | 22.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.55 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.65 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.84 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 768 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 105 |
| Lisinopril | Lisinopril | 292 | 84 |
| Metformin Hcl | Metformin Hcl | 222 | 63 |
| Omeprazole | Omeprazole | 222 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 54 |
| Losartan Potassium | Losartan Potassium | 183 | 50 |
| Alprazolam | Alprazolam | 172 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 44 |
| Allopurinol | Allopurinol | 121 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 37 |
| Simvastatin | Simvastatin | 106 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 26 |
| Methylprednisolone | Methylprednisolone | 94 | 70 |
| Trazodone Hcl | Trazodone Hcl | 94 | 28 |
| Gabapentin | Gabapentin | 92 | 30 |
| Tramadol Hcl | Tramadol Hcl | 91 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 23 |
| Alendronate Sodium | Alendronate Sodium | 82 | 23 |
| Azithromycin | Azithromycin | 79 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 24 |
| Furosemide | Furosemide | 74 | 25 |
| Eliquis | Apixaban | 67 | 16 |
| Atenolol | Atenolol | 65 | 18 |
| Meloxicam | Meloxicam | 61 | 22 |
| Sertraline Hcl | Sertraline Hcl | 60 | 19 |
| Valacyclovir | Valacyclovir Hcl | 59 | 15 |
| Fenofibrate | Fenofibrate | 58 | 19 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Finasteride | Finasteride | 50 | 16 |
| Carvedilol | Carvedilol | 48 | 17 |
| Ozempic | Semaglutide | 48 | suppressed |
| Lorazepam | Lorazepam | 47 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 43 |
| Ezetimibe | Ezetimibe | 44 | 18 |
| Propranolol Hcl | Propranolol Hcl | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 31 |
| Famotidine | Famotidine | 37 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 25 |
| Diazepam | Diazepam | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 11 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 15 |
| Prednisone | Prednisone | 22 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Estradiol | Estradiol | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.55 · 7 records | Amgen Inc. | EVENITY, LEQVIO, QULIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error